Anthony Hagen
Advertisement
Articles by Anthony Hagen
The FDA will reassess 6 indications for immune checkpoint inhibitors that were granted accelerated approval but failed to prove clinical benefit in confirmatory trials.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Pharmacists Bridge the Vaccine Trust Gap as COVID-19 Persists
2
FDA Approves Pirtobrutinib for Untreated CLL/SLL Without 17p Deletion
3
Pipeline Advances in Sjögren Disease Bring Targeted Therapies Closer
4
Who Recommends COVID-19 Vaccines Without ACIP?
5